Efficacy Of Azacitidine VersusLow-Dose Cytarabine In Patients With Acute Myeloid Leukemia - A Retrospective Single Center Experience

Azacitidine (AZA) treatment has been shown to be superior to conventional care regimens including low dose cytarabine (LD-Ara-C) in acute myeloid leukemia (AML) patients with low bone marrow (BM) blast counts (20-30%). In contrast, data on efficacy of AZA in patients with blast counts exceeding 30% are scarce. Here we present a retrospective, single center analysis, comparing the efficacy and toxicity of AZA versusLD-Ara-C in AML patients with high BM blast counts (≥30%) prior to treatment.